ABSTRACT
On the basis of currently available evidence, ezetimibe offers a well-tolerated additional string to the bow of LDL lowering in high-risk patients. A trial of ezetimibe versus placebo added to simvastatin 20 mg daily on CVD outcomes is under way in chronic renal failure.120
